Entera Bio Ltd. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd. on June 29, 2023. The Company is organized under the laws of Israel and its ordinary shares trade on the Nasdaq Capital Market under the symbol "ENTX". The report addresses a regulatory notice received from the Nasdaq Stock Market LLC regarding listing compliance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing status rather than financial performance metrics.
Material Changes
The primary material event is the receipt of a notice from Nasdaq stating that the Company's ordinary shares failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This determination was based on the closing bid price for the 30 consecutive business days prior to June 29, 2023.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending December 26, 2023, to regain compliance.
- Requirements: To regain compliance, the closing bid price must be at least $1.00 for at least 10 consecutive business days prior to the deadline.
- Secondary Compliance: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period. Qualification requires meeting the market value of publicly held shares and other initial listing standards, potentially necessitating a reverse stock split.
- Delisting Risk: Failure to qualify for or succeed in the second compliance period could result in a determination to delist the shares, subject to an appeal process.
- Operational Impact: Management states that receipt of the Notice has no effect on the Company's business operations.
Key Facts for Investor Verification
- Verify the current closing bid price of ENTX shares to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential implementation of a reverse stock split.
- Track the Company's progress toward the December 26, 2023, compliance deadline.
- Review subsequent filings for updates on the market value of publicly held shares if a second compliance period is pursued.